Brett C Bookser

This inventor holds 22 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Metabasis Therapeutics, Inc., Dart Neuroscience, LLC, Dart Neuroscience, (Cayman) Ltd.. Active years: 1998-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brett C Bookser. Retrieved from https://idiyas.com/inventor/brett-c-bookser

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 9)

% Patents Active = 81.8

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 8 (Patent Applications = 12)

Average Co-Inventor Count = 7.3

ph-index = 4

Forward Citations = 61(Granted Patents)

Location History:

Solana Beach, CA (US) (1998)
San Diego, CA (US) (2005 - 2024)

Company Filing History:

11 out of 64

Metabasis Therapeutics, Inc.

patents

5 out of 16

Dart Neuroscience, LLC

patents

2 out of 41

Dart Neuroscience, (Cayman) Ltd.

patents

4. 2 out of 2,405

Merck Sharp + Dohme Corp.

patents

5. 2 out of 1,167

Vertex Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 1998-2026

Loading Chart...

Areas of Expertise:

NOP Inhibitors

GlyT1 Inhibitors

Glucokinase Activators

PDE1 Inhibitors

DGAT-1 Inhibitors

Anti-Diabetic Agents

Cystic Fibrosis Modulators

Nucleoside Prodrugs

Aryl Fructose Inhibitors

Phenyl Phosphonate Inhibitors

Adenosine Monophosphate Deaminase Inhibitors

Cyclohexyl Compounds

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12643888 - Substituted cyclohexyl compounds as NOP inhibitors (2026-06-02),

2. 12324802 - Modulators of cystic fibrosis transmembrane conductance regulator (2025-06-10),

3. 12269831 - Modulators of cystic fibrosis transmembrane conductance regulator (2025-04-08),

4. 12006325 - Substituted furanopyrimidine compounds as PDE1 inhibitors (2024-06-11),

5. 11945808 - Substituted cyclohexyl compounds as NOP inhibitors (2024-04-02),

6. 11434247 - Substituted furanopyrimidine compounds as PDE1 inhibitors (2022-09-06),

7. 11365191 - Substituted cyclohexyl compounds as NOP inhibiiors (2022-06-21),

8. 10709718 - Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof (2020-07-14),

9. 10174062 - Activators of glucokinase (2019-01-08),

10. 10040759 - Substituted azetidinyl compounds as GlyT1 inhibitors (2018-08-07),

11. 10034891 - Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof (2018-07-31),

12. 9708334 - Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors (2017-07-18),

13. 9522926 - Activators of glucokinase (2016-12-20),

14. 9340566 - Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof (2016-05-17),

15. 8962618 - Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof (2015-02-24),

Title: Innovator Spotlight: Brett C Bookser

Introduction:

Brett C Bookser, a prolific inventor based in San Diego, CA, stands out in the field of pharmacology with a remarkable portfolio of 19 patents. His groundbreaking contributions have significantly impacted various areas of healthcare and treatment modalities.

Latest Patents:

Among his recent patents are the development of Substituted furanopyrimidine compounds as PDE1 inhibitors. These chemical entities have shown immense potential in metabolic and reaction kinetic studies, radioactive therapies, and treating a wide range of disorders mediated by PDE1 activity or dopaminergic signaling. Additionally, his work on Substituted cyclohexyl compounds as NOP inhibitors showcases his innovative approach towards addressing neurological disorders, CNS disorders, trauma-dependent losses of function, and other peripheral disorders.

Career Highlights:

Brett C Bookser has made significant strides in the pharmaceutical industry, having worked with esteemed companies like Metabasis Therapeutics, Inc. and Dart Neuroscience, LLC. His tenure in these organizations has been marked by a dedication to pushing the boundaries of scientific research and drug development, leading to groundbreaking innovations in the field.

Collaborations:

Throughout his career, Brett C Bookser has collaborated with industry stalwarts such as Mark D Erion and Nicholas Brian Raffaele. These partnerships have been instrumental in driving forward his inventive pursuits and fostering a culture of collaboration and knowledge-sharing within the scientific community.

Conclusion:

In conclusion, Brett C Bookser's inventive spirit and passion for advancing healthcare technologies have cemented his reputation as a trailblazer in the field of pharmacology. His relentless pursuit of innovation and collaboration serves as an inspiration to aspiring inventors and underscores the transformative power of dedicated research and development in shaping the future of healthcare.

Profile summary based on public USPTO records.